GlaxoSmithKline invests $360 million in post-Brexit UK manufacturing

LONDON (Reuters) - GlaxoSmithKline plans 275 million pounds ($361 million) of new investments at three drug manufacturing sites in Britain, signaling its confidence in the country despite last month's vote to leave the European Union.

Read More »